Gan & Lee Pharmaceuticals. (603087.SS)

CNY 45.54

(0.35%)

Market Cap (In CNY)

26.91 Billion

Revenue (In CNY)

2.58 Billion

Net Income (In CNY)

340.06 Million

Avg. Volume

5.47 Million

Currency
CNY
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
32.1-54.0
PE
-
EPS
-
Beta Value
1.592
ISIN
CNE100003ZH1
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Medical - Instruments & Supplies
CEO
Mr. Gan Zhongru
Employee Count
-
Website
https://www.ganlee.com
Ipo Date
2020-06-29
Details
Gan & Lee Pharmaceuticals., a biopharmaceutical company, engages in the research, development, production, and commercialization insulin analogues primarily in China. Its products include Basalin, an insulin glargine injection; Prandilin, an insulin lispro injection; Prandilin 25, an insulin lispro; Raplin, an insulin aspart injection; Raplin 30, an insulin aspart 30 injection; and Similin 30, an insulin injection, as well as medical devices. The company was formerly known as Beijing Gan & Lee Biotechnology Co., Ltd. and changed its name to Gan & Lee Pharmaceuticals. in April 2005. Gan & Lee Pharmaceuticals. was founded in 1998 and is headquartered in Beijing, the People's Republic of China.